Activating transcription factor 5, also known as ATF5, is a protein that, in humans, is encoded by the ATF5gene.[5]
Function
First described by Nishizawa and Nagata,[6] ATF5 has been classified as a member of the activating transcription factor (ATF)/cAMP response-element binding protein (CREB) family.[7][8]
ATF5 transcripts and protein are expressed in a wide variety of tissues, in particular, high expression of transcripts in liver. It is also present in a variety of tumor cell types.
ATF5 expression is regulated at both the transcriptional and translational level.
ATF5 is expressed in VZ and SVZ during brain development.
The human ATF5 protein is made up of 282 amino acids.
ATF5 is a transcription factor that contains a bZip domain.
^Hai T, Hartman MG (July 2001). "The molecular biology and nomenclature of the activating transcription factor/cAMP responsive element binding family of transcription factors: activating transcription factor proteins and homeostasis". Gene. 273 (1): 1–11. doi:10.1016/S0378-1119(01)00551-0. PMID11483355.
^Morris JA, Kandpal G, Ma L, Austin CP (Jul 2003). "DISC1 (Disrupted-In-Schizophrenia 1) is a centrosome-associated protein that interacts with MAP1A, MIPT3, ATF4/5 and NUDEL: regulation and loss of interaction with mutation". Hum. Mol. Genet. 12 (13): 1591–1608. doi:10.1093/hmg/ddg162. PMID12812986.
^Zhou Y, Li L, Liu Q, Xing G, Kuai X, Sun J, Yin X, Wang J, Zhang L, He F (May 2008). "E3 ubiquitin ligase SIAH1 mediates ubiquitination and degradation of TRB3". Cell. Signal. 20 (5): 942–948. doi:10.1016/j.cellsig.2008.01.010. PMID18276110.
Morris JA, Kandpal G, Ma L, Austin CP (2004). "DISC1 (Disrupted-In-Schizophrenia 1) is a centrosome-associated protein that interacts with MAP1A, MIPT3, ATF4/5 and NUDEL: regulation and loss of interaction with mutation". Hum. Mol. Genet. 12 (13): 1591–1608. doi:10.1093/hmg/ddg162. PMID12812986.
Yamada S, Ohira M, Horie H, Ando K, Takayasu H, Suzuki Y, Sugano S, Hirata T, Goto T, Matsunaga T, Hiyama E, Hayashi Y, Ando H, Suita S, Kaneko M, Sasaki F, Hashizume K, Ohnuma N, Nakagawara A (2004). "Expression profiling and differential screening between hepatoblastomas and the corresponding normal livers: identification of high expression of the PLK1 oncogene as a poor-prognostic indicator of hepatoblastomas". Oncogene. 23 (35): 5901–5911. doi:10.1038/sj.onc.1207782. PMID15221005. S2CID3114318.
Liu W, Sun M, Jiang J, Shen X, Sun Q, Liu W, Shen H, Gu J (2004). "Cyclin D3 interacts with human activating transcription factor 5 and potentiates its transcription activity". Biochem. Biophys. Res. Commun. 321 (4): 954–960. doi:10.1016/j.bbrc.2004.07.053. PMID15358120.
Al Sarraj J, Vinson C, Thiel G (2005). "Regulation of asparagine synthetase gene transcription by the basic region leucine zipper transcription factors ATF5 and CHOP". Biol. Chem. 386 (9): 873–879. doi:10.1515/BC.2005.102. PMID16164412. S2CID24061972.
Angelastro JM, Canoll PD, Kuo J, Weicker M, Costa A, Bruce JN, Greene LA (2006). "Selective destruction of glioblastoma cells by interference with the activity or expression of ATF5". Oncogene. 25 (6): 907–916. doi:10.1038/sj.onc.1209116. PMID16170340. S2CID19581052.
Wei Y, Jiang J, Sun M, Chen X, Wang H, Gu J (2006). "ATF5 increases cisplatin-induced apoptosis through up-regulation of cyclin D3 transcription in HeLa cells". Biochem. Biophys. Res. Commun. 339 (2): 591–596. doi:10.1016/j.bbrc.2005.11.054. PMID16300731.
Kakiuchi C, Ishiwata M, Nanko S, Kunugi H, Minabe Y, Nakamura K, Mori N, Fujii K, Yamada K, Yoshikawa T, Kato T (2007). "Association analysis of ATF4 and ATF5, genes for interacting-proteins of DISC1, in bipolar disorder". Neurosci. Lett. 417 (3): 316–321. doi:10.1016/j.neulet.2007.02.054. PMID17346882. S2CID7488805.
